Adaptimmune Therapeutics plc (F:473A) — Market Cap & Net Worth
Market Cap & Net Worth: Adaptimmune Therapeutics plc (473A)
Adaptimmune Therapeutics plc (F:473A) has a market capitalization of $42.94 Million (€36.73 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #22555 globally and #1980 in its home market, demonstrating a -16.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adaptimmune Therapeutics plc's stock price €0.16 by its total outstanding shares 265051591 (265.05 Million). Also see 473A total asset value for a full breakdown of the balance sheet.
Adaptimmune Therapeutics plc Market Cap History: 2015 to 2025
Adaptimmune Therapeutics plc's market capitalization history from 2015 to 2025. Data shows change from $3.17 Billion to $50.20 Million (-31.07% CAGR). Also see 473A cash flow metrics for how efficiently the company converts equity into cash flow.
Adaptimmune Therapeutics plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adaptimmune Therapeutics plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Adaptimmune Therapeutics plc (473A) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.91x
Adaptimmune Therapeutics plc's market cap is 0.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.17 Billion | $14.20 Million | -$71.58 Million | 82.61x | N/A |
| 2017 | $1.79 Billion | $37.83 Million | -$70.14 Million | 47.19x | N/A |
| 2018 | $1.29 Billion | $59.51 Million | -$95.51 Million | 21.66x | N/A |
| 2019 | $393.54 Million | $1.12 Million | -$137.16 Million | 350.75x | N/A |
| 2020 | $1.29 Billion | $3.96 Million | -$130.09 Million | 325.69x | N/A |
| 2021 | $997.79 Million | $6.15 Million | -$158.09 Million | 162.27x | N/A |
| 2022 | $390.44 Million | $27.15 Million | -$165.46 Million | 14.38x | N/A |
| 2023 | $181.28 Million | $60.28 Million | -$113.87 Million | 3.01x | N/A |
| 2024 | $162.68 Million | $178.03 Million | -$70.81 Million | 0.91x | N/A |
Competitor Companies of 473A by Market Capitalization
Companies near Adaptimmune Therapeutics plc in the global market cap rankings as of September 19, 2026. Review 473A tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Adaptimmune Therapeutics plc by market ranking:
- DESWELL INDS INC. DL-01 (F:DW2): Ranked #22546 globally with a market cap of $43.03 Million USD ( €36.80 Million EUR).
- Spuntech (TA:SPNTC): Ranked #22547 globally with a market cap of $43.02 Million USD ( ILA16.05 Billion ILA).
- Next Bt Co. Ltd (KQ:065170): Ranked #22556 globally with a market cap of $42.93 Million USD ( ₩63.36 Billion KRW).
- Huvis Corporation (KO:079980): Ranked #22557 globally with a market cap of $42.89 Million USD ( ₩63.29 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #22546 | DESWELL INDS INC. DL-01 | F:DW2 | $43.03 Million | €2.70 |
| #22547 | Spuntech | TA:SPNTC | $43.02 Million | ILA241.60 |
| #22556 | Next Bt Co. Ltd | KQ:065170 | $42.93 Million | ₩2270.00 |
| #22557 | Huvis Corporation | KO:079980 | $42.89 Million | ₩1923.00 |
Adaptimmune Therapeutics plc Historical Marketcap From 2015 to 2025
Between 2015 and today, Adaptimmune Therapeutics plc's market cap moved from $3.17 Billion to $ 50.20 Million, with a yearly change of -31.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €50.20 Million | -69.14% |
| 2024 | €162.68 Million | -10.26% |
| 2023 | €181.28 Million | -53.57% |
| 2022 | €390.44 Million | -60.87% |
| 2021 | €997.79 Million | -22.60% |
| 2020 | €1.29 Billion | +227.56% |
| 2019 | €393.54 Million | -69.47% |
| 2018 | €1.29 Billion | -27.80% |
| 2017 | €1.79 Billion | +52.23% |
| 2016 | €1.17 Billion | -62.95% |
| 2015 | €3.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Adaptimmune Therapeutics plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $42.94 Million USD |
| MoneyControl | $42.94 Million USD |
| MarketWatch | $42.94 Million USD |
| marketcap.company | $42.94 Million USD |
| Reuters | $42.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatmen… Read more